Effect of trifunctional bispecific antibody (BiLu) on GVHD and GVT induction by C57 spleen cells in mice inoculated with a lethal dose of melanoma cells
. | . | Cause of death, no. . | . | . | |
|---|---|---|---|---|---|
| Effector cells and BiLu pretreatment . | Median survival, d (range) . | Tumor . | GVHD . | No. disease-free survivors . | |
| No splenocytes | |||||
| No BiLu pretreatment | 21 (17-34) | 68 | NA | 0 | |
| BiLu pretreatment | > 220 (30-> 220) | 7 | NA | 10 | |
| Splenocytes | |||||
| No BiLu pretreatment | 19 (14-39) | 1* | 31 | 0 | |
| BiLu pretreatment | > 220 (26-> 220) | 6* | 4 | 10 | |
. | . | Cause of death, no. . | . | . | |
|---|---|---|---|---|---|
| Effector cells and BiLu pretreatment . | Median survival, d (range) . | Tumor . | GVHD . | No. disease-free survivors . | |
| No splenocytes | |||||
| No BiLu pretreatment | 21 (17-34) | 68 | NA | 0 | |
| BiLu pretreatment | > 220 (30-> 220) | 7 | NA | 10 | |
| Splenocytes | |||||
| No BiLu pretreatment | 19 (14-39) | 1* | 31 | 0 | |
| BiLu pretreatment | > 220 (26-> 220) | 6* | 4 | 10 | |
F1 mice were inoculated with B16-EpCAM melanoma cells (5 × 104) 24 hours after conditioning with 4 Gy TBI. One day later, 30 × 106 naive C57 splenocytes were given intraperitoneally with or without pretreatment with BiLu (10 μg per mouse). P values are for the comparison of tumor- and GVHD-related death as well as for disease-free survivors with or without BiLu treatment. Unless otherwise indicated, P < .001.
NA indicates not applicable.
P = .006